Do antiarrhythmic agents prevent sudden death in patients with heart failure?

2017 ◽  
Vol 20 (1) ◽  
pp. 15
Author(s):  
Christopher R. Durigan ◽  
Amy Haugh ◽  
Stephen A. Wilson
Keyword(s):  
Heart Failure ◽  
Sudden Death ◽  
Antiarrhythmic Agents ◽  
Patients With Heart Failure

scholarly journals Timing of sudden death in patients with heart failure

1994 ◽  
Vol 24 (4) ◽  
pp. 963-967 ◽  
Author(s):  
Debra K. Moser ◽  
William G. Stevenson ◽  
Mary A. Woo ◽  
Lynne W. Stevenson
Keyword(s):  
Heart Failure ◽  
Sudden Death ◽  
Patients With Heart Failure

Ambulatory Ventricular Arrhythmias in Patients With Heart Failure Do Not Specifically Predict an Increased Risk of Sudden Death

Circulation ◽  
2000 ◽  
Vol 101 (1) ◽  
pp. 40-46 ◽  
Author(s):  
John R. Teerlink ◽  
Muhammad Jalaluddin ◽  
Susan Anderson ◽  
Marrick L. Kukin ◽  
Eric J. Eichhorn ◽  
...  
Keyword(s):  
Heart Failure ◽  
Sudden Death ◽  
Ventricular Arrhythmias ◽  
Increased Risk ◽  
Patients With Heart Failure

A Review of Carvedilol Arrhythmia Data in Clinical Trials

2005 ◽  
Vol 10 (4_suppl) ◽  
pp. S59-S68 ◽  
Author(s):  
Peter R. Kowey
Keyword(s):  
Heart Failure ◽  
Atrial Fibrillation ◽  
Clinical Trials ◽  
Sudden Death ◽  
Large Scale ◽  
Left Ventricular ◽  
Antiarrhythmic Agents ◽  
Adrenergic Blockade ◽  
Variable Effect ◽  
Β Blockers

β-Blockers are currently being evaluated more intensively to define their role in clinical use as antiarrhythmic agents. β-Adrenergic blockade has been studied in relation to atrial fibrillation, ventricular arrhythmias, and sudden death; however, it is apparent from a number of studies that not all β-blockers are equally effective. Randomized clinical trial data, both in heart failure and post-myocardial infarction (MI) patients, have shown differences in mortality benefits in addition to a variable effect on arrhythmias and sudden death. Carvedilol, a third-generation β-blocker with proven clinical benefit in the management of heart failure and post-MI patients, has properties that may make it an effective antiarrhythmic agent. This paper reviews the current clinical arrhythmia data available for carvedilol from large-scale clinical trials and small studies. The trial evidence demonstrates that carvedilol therapy can be an effective adjunctive rate-control therapy in patients with atrial fibrillation, prevent mortality in patients with heart failure or post-MI with left ventricular dysfunction, with or without atrial fibrillation, and reduce its onset and the incidence of ventricular arrhythmia and sudden death.

Risk Stratification and Prevention of Sudden Death in Patients With Heart Failure

2004 ◽  
Vol 57 (8) ◽  
pp. 768-782
Author(s):  
Julián Villacastín ◽  
Ramón Bover ◽  
Nicasio P. Castellano ◽  
Javier Moreno ◽  
Ricardo Morales ◽  
...  
Keyword(s):  
Heart Failure ◽  
Sudden Death ◽  
Risk Stratification ◽  
Patients With Heart Failure

scholarly journals Acute isoproterenol leads to age-dependent arrhythmogenesis in guinea pigs

2018 ◽  
Vol 315 (4) ◽  
pp. H1051-H1062 ◽  
Author(s):  
Kathleen C. Woulfe ◽  
Cortney E. Wilson ◽  
Shane Nau ◽  
Sarah Chau ◽  
Elisabeth K. Phillips ◽  
...  
Keyword(s):  
Heart Failure ◽  
Sudden Death ◽  
Guinea Pigs ◽  
Pediatric Patients ◽  
Left Ventricular ◽  
Adult Patients ◽  
Adrenergic Stimulation ◽  
Premature Ventricular Contractions ◽  
Age Related ◽  
Patients With Heart Failure

Sudden cardiac death from ventricular arrhythmias is more common in adult patients with with heart failure compared with pediatric patients with heart failure. We identified age-specific differences in arrhythmogenesis using a guinea pig model of acute β-adrenergic stimulation. Young and adult guinea pigs were exposed to the β-adrenergic agonist isoproterenol (ISO; 0.7 mg/kg) for 30 min in the absence or presence of flecainide (20 mg/kg), an antiarrhythmic that blocks Na+ and ryanodine channels. Implanted cardiac monitors (Reveal LINQ, Medtronic) were used to monitor heart rhythm. Alterations in phosphorylation and oxidation of ryanodine receptor 2 (RyR2) were measured in left ventricular tissue. There were age-specific differences in arrhythmogenesis and sudden death associated with acute β-adrenergic stimulation in guinea pigs. Young and adult guinea pigs developed arrhythmias in response to ISO; however, adult animals developed significantly more premature ventricular contractions and experienced higher arrhythmia-related mortality than young guinea pigs treated with ISO. Although there were no significant differences in the phosphorylation of left ventricular RyR2 between young and adult guinea pigs, adult guinea pigs exposed to acute ISO had significantly more oxidation of RyR2. Flecainide treatment significantly improved survival and decreased the number of premature ventricular contractions in young and adult animals in association with lower RyR2 oxidation. Adult guinea pigs had a greater propensity to develop arrhythmias and suffer sudden death than young guinea pigs when acutely exposed to ISO. This was associated with higher oxidation of RyR2. The incidence of sudden death can be rescued with flecainide treatment, which decreases RyR2 oxidation. NEW & NOTEWORTHY Clinically, adult patients with heart failure are more likely to develop arrhythmias and sudden death than pediatric patients with heart failure. In the present study, older guinea pigs also showed a greater propensity to arrhythmias and sudden death than young guinea pigs when acutely exposed to isoproterenol. Although there are well-described age-related cardiac structural changes that predispose patients to arrhythmogenesis, the present data suggest contributions from dynamic changes in cellular signaling also play an important role in arrhythmogenesis.

scholarly journals A LITERATURE REVIEW: LOW SODIUM RESTRICTION OF PATIENTS WITH HEART FAILURE ON HOSPITAL READMISSION

2021 ◽  
Vol 9 (2) ◽  
pp. 128
Author(s):  
Septa Meriana Lumbantoruan
Keyword(s):  
Heart Failure ◽  
Literature Review ◽  
Sudden Death ◽  
Beneficial Effect ◽  
Hospital Readmission ◽  
Sodium Intake ◽  
Experimental Studies ◽  
Sodium Restriction ◽  
Low Sodium ◽  
Patients With Heart Failure

<p>Sodium restriction effect on hospital readmission in patients with heart failure (HF) has been questioned for decades. Readmission related to low sodium intake recommendations should be changed as well as mortality. A literature review is needed to summarize the effect of low sodium, especially on readmission and mortality. This literature review aimed to summarize the prevalence of hospital readmission and mortality regarding low sodium intake in patients with HF. The searching process involved four databases; MEDLINE, Embase, EBSCO Health, Cochrane was explored for experimental studies of sodium restriction. Of 77 screened citations from 2000 to 2019 invested in patients with HF, four studies were included. Four studies from four databases were included and explained and it was found that hospital readmission was the outcome of implementing sodium restriction in patients with HF. Low sodium restriction (800 mg – 1800 mg/day) results in higher hospital readmission. Moreover, 1800 mg/day of sodium was followed by higher mortality and higher sudden death in patients with HF. Low sodium restriction did not lower hospital readmission as well as mortality of patients with HF. This article provides the reason, effect, and amount of sodium restriction in patients with HF. The recommendation from this literature review is low sodium restriction has no beneficial effect on readmission and mortality in HF conditions.</p>

Sign in / Sign up

Export Citation Format

Share Document